Gene Editing and Human iPSCs in Cardiovascular and Metabolic Diseases

Adv Exp Med Biol. 2023:1396:275-298. doi: 10.1007/978-981-19-5642-3_18.

Abstract

The incidence and the burden of cardiovascular disease (CVD), coronary heart disease (CHD), type 2 diabetes mellitus (T2DM), and the metabolic syndrome are greatly increasing in our societies. Together, they account for 31% of all deaths worldwide. This chapter focuses on the role of two revolutionary discoveries that are changing the future of medicine, induced pluripotent stem cells (iPSCs) and CRISPR/Cas9 technology, in the study, and the cure of cardiovascular and metabolic diseases.We summarize the state-of-the-art knowledge about the possibility of editing iPSC genome for therapeutic applications without hampering their pluripotency and differentiation, using CRISPR/Cas technology, in the field of cardiovascular and metabolic diseases.

Keywords: Cardiovascular; Epigenetics; Gene editing; Induced pluripotent stem cells (iPSC); Metabolism.

MeSH terms

  • Cardiovascular System*
  • Diabetes Mellitus, Type 2* / genetics
  • Diabetes Mellitus, Type 2* / therapy
  • Gene Editing
  • Humans
  • Induced Pluripotent Stem Cells*
  • Metabolic Diseases* / genetics
  • Metabolic Diseases* / therapy